Results 51 to 60 of about 4,828 (174)
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 11, Page 1835-1847, November 2025.ABSTRACT Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH.
Sébastien Bihorel +18 more
wiley +1 more source
International Journal of General Medicine, 2018 Ahmad Abushahin, Ibrahim Janahi, Amjad Tuffaha Department of Pediatrics, Section of Pediatric Pulmonology, Hamad Medical Corporation, Doha, Qatar Objective: The primary objective of this study was to document the hospitalization rate due to ...
Abushahin A, Janahi I, Tuffaha A
doaj
Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3
Reviews in Medical Virology, Volume 35, Issue 6, November 2025.ABSTRACT Human parainfluenza virus‐type 3 (HPIV3) is a respiratory virus responsible for mild illnesses in most of the population and severe illnesses, such as bronchiolitis and pneumonia, in young children, immunocompromised individuals and the elderly.
Clémence Vacher +4 more
wiley +1 more source
Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey
The Turkish Journal of Pediatrics, 2012 The main aim of this study was to evaluate the cost-effectiveness of respiratory syncytial virus (RSV) prophylaxis with palivizumab in Turkey, by comparing hospitalization rates and costs as well as results of risk analyses in preterm infants who ...
Mehmet Yekta Oncel +7 more
doaj
Journal of Clinical QuestionIntroduction: Respiratory syncytial virus (RSV) is a leading cause of LRTI and hospitalization in infants and young children. Passive immunization with monoclonal antibodies represents a major strategy for RSV prevention.
Tetsuya Nosho +3 more
doaj +1 more source
The clinical significance of palivi-zumab in the prevention of severe respiratory infections in newborn infants [PDF]
Саратовский научно-медицинский журнал, 2016 Palivizumab is known as the world's first drug with proven efficacy for passive immunization of severe infections of lower respiratory tract in preterm infants.
Bykova Е.М. +5 more
doaj
BMC Research Notes, 2012 Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in children globally. Predisposing conditions for the development of serious RSV disease include preterm infants and those with cardiopulmonary ...
Turti Tatyana V +10 more
doaj +1 more source
Palivizumab prophylaxis of RSV infections in Bosnia and Herzegovina
Journal of Pediatric and Neonatal Individualized Medicine, 2016 Background: Palivizumab is indicated for respiratory syncytial virus (RSV) prophylaxis in high-risk children. Methods: Observational study, based on 4 sites in Bosnia and Herzegovina (B&H), with institutional reports of infants at high risk for RSV ...
Suada Heljic +8 more
doaj +1 more source
Palivizumab and RSV prevention [PDF]
Archives of Disease in Childhood, 2000 Editor,—The letters from Drs Deshpande and Nicholl, in relation to the Impact-RSV study and the UK guidance for the use of palivizumab in the prevention of serious RSV infections, raise interesting questions that need to be addressed. I believe Dr Deshpande “has got it wrong” in that he fails to realise that the primary objective of the IMpact study ...
openaire +1 more source
BMC Pediatrics, 2009 Background Bronchiolitis is a distressing, potentially life-threatening respiratory condition that affects infants. We evaluated the incidence and risk factors of hospitalization for broncholitis in preterm infants (i.e., a gestational age of
Mucchino Eleonora +4 more
doaj +1 more source